{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-060202","form_type":"8-K","ticker":"PSNL","cik":"0001527753","company_name":"Personalis, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.377301+00:00","generated_at":"2026-06-08T14:55:03.769157+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Personalis Q3 revenue up 23% to $18.2M; raises FY2023 guidance","bullets":["Revenue $18.2M (+23% YoY); net loss $29.1M, EPS -$0.60 including $5.6M impairment.","Full-year 2023 revenue guidance raised to $73-74M (prior $70-72M); Q4 guided $19-20M.","Pharma/enterprise revenue $15.8M (+7% YoY); Natera contributed $7.9M.","TRACERx data: NeXT Personal up to 4x sensitivity vs other liquid biopsies; detects lung cancer 6-11 months before imaging.","Cash $120.7M; FY2023 cash usage <$70M vs $119M in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-060202","json":"https://secwatch.observer/filing/0000950170-23-060202.json","markdown":"https://secwatch.observer/filing/0000950170-23-060202.md","text":"https://secwatch.observer/filing/0000950170-23-060202.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527753/000095017023060202/0000950170-23-060202-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527753/000095017023060202/psnl-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T14:55:03.769157+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40e25f0e67151aa852e57095826756f88a0a47ee","claim":"Personalis, Inc. reported the third quarter ended September 30, 2023 results: revenue $18.2 million, net income $29.1 million, EPS $0.60. Guidance raised.","evidence_excerpt":"reference in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Personalis Reports Third Quarter 2023 Financial Results Increased third quarter revenue 23% to $18.2 million and increased full year guidance Presented data supporting Next Personal’s market leading sensitivity for cancer recurrence detection FREMONT, Calif. – November 7, 2023 –","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527753/000095017023060202/0000950170-23-060202-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$18.2 million"},{"label":"Net income","value":"$29.1 million"},{"label":"EPS","value":"$0.60"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}